MARKET

RARE

RARE

Ultragenyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

43.01
-1.31
-2.96%
Opening 13:30 03/31 EDT
OPEN
44.08
PREV CLOSE
44.32
HIGH
44.88
LOW
42.57
VOLUME
115.91K
TURNOVER
--
52 WEEK HIGH
74.50
52 WEEK LOW
31.99
MARKET CAP
2.49B
P/E (TTM)
-6.0383
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of RARE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RARE stock price target is 72.94 with a high estimate of 90.00 and a low estimate of 53.00.

EPS

RARE News

More
  • Hedge Funds Were Selling Ultragenyx Pharmaceutical Inc (RARE) Before The Coronavirus
  • Insider Monkey · 2d ago
  • Have Insiders Been Buying Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares This Year?
  • Simply Wall St. · 03/21 15:39
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome
  • GlobeNewswire · 03/16 13:30

Industry

Biotechnology & Medical Research
-2.23%
Pharmaceuticals & Medical Research
-1.03%

Hot Stocks

Symbol
Price
%Change

About RARE

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.
More

Webull offers kinds of Ultragenyx Pharmaceutical Inc stock information, including NASDAQ:RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions.